Detalhe da pesquisa
1.
Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo.
Blood
; 140(22): 2335-2347, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36084319
2.
Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
Blood
; 140(22): 2348-2357, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35921541
3.
What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?
Haematologica
; 109(3): 888-894, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646655
4.
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.
Hematol Oncol
; 42(1): e3216, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37772620
5.
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
Hematol Oncol
; 42(1): e3249, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38287529
6.
Unselected donor-derived hematopoietic stem cells boost for Chimeric Antigen Receptor T-cell associated hematotoxicity.
Am J Hematol
; 99(4): 751-754, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38247313
7.
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells.
Br J Haematol
; 201(1): 86-94, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36503182
8.
B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation.
Blood
; 138(12): 1053-1066, 2021 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33900379
9.
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
Blood
; 137(25): 3507-3517, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33651883
10.
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy.
Haematologica
; 108(8): 2101-2115, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36655432
11.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Haematologica
; 108(8): 2091-2100, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36632738
12.
Richter transformation in Chronic Lymphocytic Leukemia.
Hematol Oncol
; 41(3): 293-300, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36433773
13.
Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience.
Hematol Oncol
; 41(4): 621-630, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36680368
14.
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.
Hematol Oncol
; 41(3): 571-573, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35319789
15.
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.
Hematol Oncol
; 41(5): 877-883, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37392141
16.
Role of microRNAs in Chronic Lymphocytic Leukemia.
Int J Mol Sci
; 24(15)2023 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37569845
17.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(8): 1031-1043, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35810754
18.
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.
Blood
; 135(15): 1244-1254, 2020 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32006000
19.
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement.
Hematol Oncol
; 40(3): 332-340, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35212014
20.
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement.
Hematol Oncol
; 40(4): 518-527, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35247223